APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adult Preventable Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adult Preventable Vaccines Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchAdult Preventable Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Adult Preventable Vaccines Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adult Preventable Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adult Preventable Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adult Preventable Vaccines Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Adult Preventable Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adult Preventable Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adult Preventable Vaccines market include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adult Preventable Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adult Preventable Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adult Preventable Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adult Preventable Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Adult Preventable Vaccines Segment by Company

Sanofi Pasteur

Johnson & Johnson (Janssen)

Pfizer Inc.

GlaxoSmithKline plc (GSK)

Sinovac Biotech

Sinopharm Group Co.,

Serum Institute of India Pvt.

Novavax, Inc.

Moderna, Inc.

Merck & Co., Inc.

Emergent BioSolutions Inc.

Daiichi Sankyo Company

CSL Limited (Seqirus)

Bharat Biotech International

AstraZeneca plc

Adult Preventable Vaccines Segment by Type

Viral Vector Vaccines

Peptide Vaccines

Inactivated Vaccines

Subunit Vaccines

Mrna Vaccines

Adult Preventable Vaccines Segment by Application

Prevent Herpes Zoster

Prevent Pneumococcal Infection

Prevent Influenza

Prevent Human Papillomavirus (Hpv)

Prevent Hepatitis B

Other

Adult Preventable Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adult Preventable Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Adult Preventable Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adult Preventable Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Adult Preventable Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adult Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult Preventable Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adult Preventable Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adult Preventable Vaccines industry.

Chapter 3: Detailed analysis of Adult Preventable Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Adult Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Adult Preventable Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adult Preventable Vaccines Industry Trends Table 2. Adult Preventable Vaccines Industry Drivers Table 3. Adult Preventable Vaccines Industry Opportunities and Challenges Table 4. Adult Preventable Vaccines Industry Restraints Table 5. Global Adult Preventable Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adult Preventable Vaccines Revenue Share by Company (2021-2026) Table 7. Global Adult Preventable Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Adult Preventable Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Adult Preventable Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Adult Preventable Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Adult Preventable Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Adult Preventable Vaccines Company, Product Type & Application Table 13. Global Adult Preventable Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Adult Preventable Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Viral Vector Vaccines Table 18. Significant Companies of Peptide Vaccines Table 19. Significant Companies of Inactivated Vaccines Table 20. Significant Companies of Subunit Vaccines Table 21. Significant Companies of Mrna Vaccines Table 22. Global Adult Preventable Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Adult Preventable Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Adult Preventable Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Adult Preventable Vaccines Sales Volume Share by Type (2021-2026) Table 26. Global Adult Preventable Vaccines Sales Volume Share by Type (2027-2032) Table 27. Global Adult Preventable Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Adult Preventable Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Adult Preventable Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Adult Preventable Vaccines Sales Value Share by Type (2021-2026) Table 31. Global Adult Preventable Vaccines Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Prevent Herpes Zoster Table 33. Significant Companies of Prevent Pneumococcal Infection Table 34. Significant Companies of Prevent Influenza Table 35. Significant Companies of Prevent Human Papillomavirus (Hpv) Table 36. Significant Companies of Prevent Hepatitis B Table 37. Significant Companies of Other Table 38. Global Adult Preventable Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Adult Preventable Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Adult Preventable Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Adult Preventable Vaccines Sales Volume Share by Application (2021-2026) Table 42. Global Adult Preventable Vaccines Sales Volume Share by Application (2027-2032) Table 43. Global Adult Preventable Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Adult Preventable Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Adult Preventable Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Adult Preventable Vaccines Sales Value Share by Application (2021-2026) Table 47. Global Adult Preventable Vaccines Sales Value Share by Application (2027-2032) Table 48. Global Adult Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Adult Preventable Vaccines Sales by Region (2021-2026) & (K Units) Table 50. Global Adult Preventable Vaccines Sales Market Share by Region (2021-2026) Table 51. Global Adult Preventable Vaccines Sales by Region (2027-2032) & (K Units) Table 52. Global Adult Preventable Vaccines Sales Market Share by Region (2027-2032) Table 53. Global Adult Preventable Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Adult Preventable Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Adult Preventable Vaccines Sales Value Share by Region (2021-2026) Table 56. Global Adult Preventable Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Adult Preventable Vaccines Sales Value Share by Region (2027-2032) Table 58. Global Adult Preventable Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Adult Preventable Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Adult Preventable Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Adult Preventable Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Adult Preventable Vaccines Sales by Country (2021-2026) & (K Units) Table 63. Global Adult Preventable Vaccines Sales Market Share by Country (2021-2026) Table 64. Global Adult Preventable Vaccines Sales by Country (2027-2032) & (K Units) Table 65. Global Adult Preventable Vaccines Sales Market Share by Country (2027-2032) Table 66. Global Adult Preventable Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Adult Preventable Vaccines Sales Value Market Share by Country (2021-2026) Table 68. Global Adult Preventable Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Adult Preventable Vaccines Sales Value Market Share by Country (2027-2032) Table 70. Sanofi Pasteur Company Information Table 71. Sanofi Pasteur Business Overview Table 72. Sanofi Pasteur Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sanofi Pasteur Adult Preventable Vaccines Product Portfolio Table 74. Sanofi Pasteur Recent Development Table 75. Johnson & Johnson (Janssen) Company Information Table 76. Johnson & Johnson (Janssen) Business Overview Table 77. Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio Table 79. Johnson & Johnson (Janssen) Recent Development Table 80. Pfizer Inc. Company Information Table 81. Pfizer Inc. Business Overview Table 82. Pfizer Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Inc. Adult Preventable Vaccines Product Portfolio Table 84. Pfizer Inc. Recent Development Table 85. GlaxoSmithKline plc (GSK) Company Information Table 86. GlaxoSmithKline plc (GSK) Business Overview Table 87. GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio Table 89. GlaxoSmithKline plc (GSK) Recent Development Table 90. Sinovac Biotech Company Information Table 91. Sinovac Biotech Business Overview Table 92. Sinovac Biotech Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sinovac Biotech Adult Preventable Vaccines Product Portfolio Table 94. Sinovac Biotech Recent Development Table 95. Sinopharm Group Co., Company Information Table 96. Sinopharm Group Co., Business Overview Table 97. Sinopharm Group Co., Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio Table 99. Sinopharm Group Co., Recent Development Table 100. Serum Institute of India Pvt. Company Information Table 101. Serum Institute of India Pvt. Business Overview Table 102. Serum Institute of India Pvt. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio Table 104. Serum Institute of India Pvt. Recent Development Table 105. Novavax, Inc. Company Information Table 106. Novavax, Inc. Business Overview Table 107. Novavax, Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Novavax, Inc. Adult Preventable Vaccines Product Portfolio Table 109. Novavax, Inc. Recent Development Table 110. Moderna, Inc. Company Information Table 111. Moderna, Inc. Business Overview Table 112. Moderna, Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Moderna, Inc. Adult Preventable Vaccines Product Portfolio Table 114. Moderna, Inc. Recent Development Table 115. Merck & Co., Inc. Company Information Table 116. Merck & Co., Inc. Business Overview Table 117. Merck & Co., Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio Table 119. Merck & Co., Inc. Recent Development Table 120. Emergent BioSolutions Inc. Company Information Table 121. Emergent BioSolutions Inc. Business Overview Table 122. Emergent BioSolutions Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio Table 124. Emergent BioSolutions Inc. Recent Development Table 125. Daiichi Sankyo Company Company Information Table 126. Daiichi Sankyo Company Business Overview Table 127. Daiichi Sankyo Company Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio Table 129. Daiichi Sankyo Company Recent Development Table 130. CSL Limited (Seqirus) Company Information Table 131. CSL Limited (Seqirus) Business Overview Table 132. CSL Limited (Seqirus) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio Table 134. CSL Limited (Seqirus) Recent Development Table 135. Bharat Biotech International Company Information Table 136. Bharat Biotech International Business Overview Table 137. Bharat Biotech International Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Bharat Biotech International Adult Preventable Vaccines Product Portfolio Table 139. Bharat Biotech International Recent Development Table 140. AstraZeneca plc Company Information Table 141. AstraZeneca plc Business Overview Table 142. AstraZeneca plc Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. AstraZeneca plc Adult Preventable Vaccines Product Portfolio Table 144. AstraZeneca plc Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Adult Preventable Vaccines Distributors List Table 148. Adult Preventable Vaccines Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Adult Preventable Vaccines Product Image Figure 2. Global Adult Preventable Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Adult Preventable Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Adult Preventable Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Adult Preventable Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Viral Vector Vaccines Image Figure 10. Peptide Vaccines Image Figure 11. Inactivated Vaccines Image Figure 12. Subunit Vaccines Image Figure 13. Mrna Vaccines Image Figure 14. Global Adult Preventable Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Adult Preventable Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Adult Preventable Vaccines Sales Volume Share by Type (2021-2032) Figure 17. Global Adult Preventable Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Adult Preventable Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Adult Preventable Vaccines Sales Value Share by Type (2021-2032) Figure 20. Prevent Herpes Zoster Image Figure 21. Prevent Pneumococcal Infection Image Figure 22. Prevent Influenza Image Figure 23. Prevent Human Papillomavirus (Hpv) Image Figure 24. Prevent Hepatitis B Image Figure 25. Other Image Figure 26. Global Adult Preventable Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Adult Preventable Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Adult Preventable Vaccines Sales Volume Share by Application (2021-2032) Figure 29. Global Adult Preventable Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Adult Preventable Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Adult Preventable Vaccines Sales Value Share by Application (2021-2032) Figure 32. Global Adult Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Adult Preventable Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Adult Preventable Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Adult Preventable Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. North America Adult Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Adult Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Adult Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 43. South America Adult Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Adult Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Adult Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Adult Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Adult Preventable Vaccines Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Adult Preventable Vaccines Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Vector Vaccines
  • Peptide Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Mrna Vaccines
Applications
  • Prevent Herpes Zoster
  • Prevent Pneumococcal Infection
  • Prevent Influenza
  • Prevent Human Papillomavirus (Hpv)
  • Prevent Hepatitis B
  • Other
Companies covered
  • Sanofi Pasteur
  • Johnson & Johnson (Janssen)
  • Pfizer Inc.
  • GlaxoSmithKline plc (GSK)
  • Sinovac Biotech
  • Sinopharm Group Co.,
  • Serum Institute of India Pvt.
  • Novavax, Inc.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Emergent BioSolutions Inc.
  • Daiichi Sankyo Company
  • CSL Limited (Seqirus)
  • Bharat Biotech International
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Adult Preventable Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Adult Preventable Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Adult Preventable Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Adult Preventable Vaccines Market Dynamics
  1. 2.1 Adult Preventable Vaccines Industry Trends
  2. 2.2 Adult Preventable Vaccines Industry Drivers
  3. 2.3 Adult Preventable Vaccines Industry Opportunities and Challenges
  4. 2.4 Adult Preventable Vaccines Industry Restraints
3 Adult Preventable Vaccines Market by Company
  1. 3.1 Global Adult Preventable Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Adult Preventable Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Adult Preventable Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Adult Preventable Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Adult Preventable Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Adult Preventable Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Adult Preventable Vaccines Company Product Type and Application
  8. 3.8 Global Adult Preventable Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Adult Preventable Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Adult Preventable Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Adult Preventable Vaccines Market by Type
  1. 4.1 Adult Preventable Vaccines Type Introduction
  2. 4.1.1 Viral Vector Vaccines
  3. 4.1.2 Peptide Vaccines
  4. 4.1.3 Inactivated Vaccines
  5. 4.1.4 Subunit Vaccines
  6. 4.1.5 Mrna Vaccines
  7. 4.2 Global Adult Preventable Vaccines Sales Volume by Type
  8. 4.2.1 Global Adult Preventable Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Adult Preventable Vaccines Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Adult Preventable Vaccines Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Adult Preventable Vaccines Sales Value by Type
  12. 4.3.1 Global Adult Preventable Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Adult Preventable Vaccines Sales Value by Type (2021-2032)
  14. 4.3.3 Global Adult Preventable Vaccines Sales Value Share by Type (2021-2032)
5 Adult Preventable Vaccines Market by Application
  1. 5.1 Adult Preventable Vaccines Application Introduction
  2. 5.1.1 Prevent Herpes Zoster
  3. 5.1.2 Prevent Pneumococcal Infection
  4. 5.1.3 Prevent Influenza
  5. 5.1.4 Prevent Human Papillomavirus (Hpv)
  6. 5.1.5 Prevent Hepatitis B
  7. 5.1.6 Other
  8. 5.2 Global Adult Preventable Vaccines Sales Volume by Application
  9. 5.2.1 Global Adult Preventable Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Adult Preventable Vaccines Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Adult Preventable Vaccines Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Adult Preventable Vaccines Sales Value by Application
  13. 5.3.1 Global Adult Preventable Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Adult Preventable Vaccines Sales Value by Application (2021-2032)
  15. 5.3.3 Global Adult Preventable Vaccines Sales Value Share by Application (2021-2032)
6 Adult Preventable Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Adult Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adult Preventable Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Adult Preventable Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Adult Preventable Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Adult Preventable Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Adult Preventable Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Adult Preventable Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Adult Preventable Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Adult Preventable Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Adult Preventable Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Adult Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Adult Preventable Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Adult Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Adult Preventable Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Adult Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Adult Preventable Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Adult Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Adult Preventable Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Adult Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
7 Adult Preventable Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Adult Preventable Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adult Preventable Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Adult Preventable Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Adult Preventable Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Adult Preventable Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Adult Preventable Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Adult Preventable Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Adult Preventable Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Adult Preventable Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Adult Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Adult Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Adult Preventable Vaccines Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 Johnson & Johnson (Janssen)
  8. 8.2.1 Johnson & Johnson (Janssen) Company Information
  9. 8.2.2 Johnson & Johnson (Janssen) Business Overview
  10. 8.2.3 Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio
  12. 8.2.5 Johnson & Johnson (Janssen) Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Adult Preventable Vaccines Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc (GSK)
  20. 8.4.1 GlaxoSmithKline plc (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline plc (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc (GSK) Recent Developments
  25. 8.5 Sinovac Biotech
  26. 8.5.1 Sinovac Biotech Company Information
  27. 8.5.2 Sinovac Biotech Business Overview
  28. 8.5.3 Sinovac Biotech Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Biotech Adult Preventable Vaccines Product Portfolio
  30. 8.5.5 Sinovac Biotech Recent Developments
  31. 8.6 Sinopharm Group Co.,
  32. 8.6.1 Sinopharm Group Co., Company Information
  33. 8.6.2 Sinopharm Group Co., Business Overview
  34. 8.6.3 Sinopharm Group Co., Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio
  36. 8.6.5 Sinopharm Group Co., Recent Developments
  37. 8.7 Serum Institute of India Pvt.
  38. 8.7.1 Serum Institute of India Pvt. Company Information
  39. 8.7.2 Serum Institute of India Pvt. Business Overview
  40. 8.7.3 Serum Institute of India Pvt. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio
  42. 8.7.5 Serum Institute of India Pvt. Recent Developments
  43. 8.8 Novavax, Inc.
  44. 8.8.1 Novavax, Inc. Company Information
  45. 8.8.2 Novavax, Inc. Business Overview
  46. 8.8.3 Novavax, Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novavax, Inc. Adult Preventable Vaccines Product Portfolio
  48. 8.8.5 Novavax, Inc. Recent Developments
  49. 8.9 Moderna, Inc.
  50. 8.9.1 Moderna, Inc. Company Information
  51. 8.9.2 Moderna, Inc. Business Overview
  52. 8.9.3 Moderna, Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Moderna, Inc. Adult Preventable Vaccines Product Portfolio
  54. 8.9.5 Moderna, Inc. Recent Developments
  55. 8.10 Merck & Co., Inc.
  56. 8.10.1 Merck & Co., Inc. Company Information
  57. 8.10.2 Merck & Co., Inc. Business Overview
  58. 8.10.3 Merck & Co., Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio
  60. 8.10.5 Merck & Co., Inc. Recent Developments
  61. 8.11 Emergent BioSolutions Inc.
  62. 8.11.1 Emergent BioSolutions Inc. Company Information
  63. 8.11.2 Emergent BioSolutions Inc. Business Overview
  64. 8.11.3 Emergent BioSolutions Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio
  66. 8.11.5 Emergent BioSolutions Inc. Recent Developments
  67. 8.12 Daiichi Sankyo Company
  68. 8.12.1 Daiichi Sankyo Company Company Information
  69. 8.12.2 Daiichi Sankyo Company Business Overview
  70. 8.12.3 Daiichi Sankyo Company Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio
  72. 8.12.5 Daiichi Sankyo Company Recent Developments
  73. 8.13 CSL Limited (Seqirus)
  74. 8.13.1 CSL Limited (Seqirus) Company Information
  75. 8.13.2 CSL Limited (Seqirus) Business Overview
  76. 8.13.3 CSL Limited (Seqirus) Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio
  78. 8.13.5 CSL Limited (Seqirus) Recent Developments
  79. 8.14 Bharat Biotech International
  80. 8.14.1 Bharat Biotech International Company Information
  81. 8.14.2 Bharat Biotech International Business Overview
  82. 8.14.3 Bharat Biotech International Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bharat Biotech International Adult Preventable Vaccines Product Portfolio
  84. 8.14.5 Bharat Biotech International Recent Developments
  85. 8.15 AstraZeneca plc
  86. 8.15.1 AstraZeneca plc Company Information
  87. 8.15.2 AstraZeneca plc Business Overview
  88. 8.15.3 AstraZeneca plc Adult Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca plc Adult Preventable Vaccines Product Portfolio
  90. 8.15.5 AstraZeneca plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adult Preventable Vaccines Value Chain Analysis
  2. 9.1.1 Adult Preventable Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adult Preventable Vaccines Sales Mode & Process
  6. 9.2 Adult Preventable Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adult Preventable Vaccines Distributors
  9. 9.2.3 Adult Preventable Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst